Cover Image
市場調查報告書

Orphagen Pharmaceuticals, Inc.:產品平台分析

Orphagen Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 314191
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Orphagen Pharmaceuticals, Inc.:產品平台分析 Orphagen Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年06月30日 內容資訊: 英文 22 Pages
簡介

Orphagen Pharmaceuticals, Inc.是開發以核內孤兒受體為標的的小分子藥之製藥公司。這個核內受體包含了自體免疫疾病、睡眠·覺醒障礙、代謝疾病、心理障礙。

本報告提供Orphagen Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,以及後期階段及中止的計劃等相關資訊。

Orphagen Pharmaceuticals, Inc.的基本資料

Orphagen Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Orphagen Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Orphagen Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Orphagen Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 藥物研發中的產品/聯合治療模式

Orphagen Pharmaceuticals, Inc.:藥物簡介

  • OR-1050
  • Steroidogenic 遮斷Factor-1的小分子
  • 面向調節核受體的生理節律睡眠障礙小分子
  • 面向調節核受體的AMD小分子
  • 面向調節核受體的GBM小分子
  • 面向調節核受體的色素性視網膜炎小分子

Orphagen Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Orphagen Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07219CDB

Summary

Global Markets Direct's, 'Orphagen Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Orphagen Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Orphagen Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Orphagen Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Orphagen Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Orphagen Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Orphagen Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Orphagen Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Orphagen Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Orphagen Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Orphagen Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Orphagen Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Orphagen Pharmaceuticals, Inc. Snapshot
    • Orphagen Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Orphagen Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Orphagen Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products Glance
    • Orphagen Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Orphagen Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Orphagen Pharmaceuticals, Inc. - Drug Profiles
    • OR-1050
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for AMD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Glioblastoma Multiforme
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Retinitis Pigmentosa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Orphagen Pharmaceuticals, Inc. - Pipeline Analysis
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Target
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Orphagen Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Orphagen Pharmaceuticals, Inc., Key Information
  • Orphagen Pharmaceuticals, Inc., Key Facts
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Orphagen Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Orphagen Pharmaceuticals, Inc. - Phase I, 2015
  • Orphagen Pharmaceuticals, Inc. - Discovery, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Orphagen Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Orphagen Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top